Psilocybin-induced stimulus control in the rat

Although psilocybin has been trained in the rat as a discriminative stimulus, little is known of the pharmacological receptors essential for stimulus control. In the present investigation rats were trained with psilocybin and tests were then conducted employing a series of other hallucinogens and presumed antagonists. An intermediate degree of antagonism of psilocybin was observed following treatment with the 5-HT(2A) receptor antagonist, M100907. In contrast, no significant antagonism was observed following treatment with the 5-HT(1A/7) receptor antagonist, WAY-100635, or the DA D(2) antagonist, remoxipride. Psilocybin generalized fully to DOM, LSD, psilocin, and, in the presence of WAY-100635, DMT while partial generalization was seen to 2C-T-7 and mescaline. LSD and MDMA partially generalized to psilocybin and these effects were completely blocked by M-100907; no generalization of PCP to psilocybin was seen. The present data suggest that psilocybin induces a compound stimulus in which activity at the 5-HT(2A) receptor plays a prominent but incomplete role. In addition, psilocybin differs from closely related hallucinogens such as 5-MeO-DMT in that agonism at 5-HT(1A) receptors appears to play no role in psilocybin-induced stimulus control.

[1]  J. C. Winter.  The stimulus properties of para-methoxyamphetamine: A nonessential serotonergic component , 1984, Pharmacology Biochemistry and Behavior.

[2]  J. B. Appel,et al.  Assessment of the discriminative stimulus effects of the optical isomers of ecstasy (3,4‐methylenedioxymethamphetamine; MDMA) , 1995, Behavioural pharmacology.

[3]  A. Horita.  Some biochemical studies on psilocybin and psilogin. , 1963, Journal of neuropsychiatry.

[4]  J. C. Winter,et al.  The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs III: the mechanistic basis for supersensitivity to the LSD stimulus following serotonin depletion , 1995, Psychopharmacology.

[5]  P. B. Silverman,et al.  The discriminative stimulus properties of 2,5-dimethoxy-4-methylamphetamine (DOM): Differentiation from amphetamine , 2004, Psychopharmacology.

[6]  R. Griffiths,et al.  Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance , 2006, Psychopharmacology.

[7]  K. Cunningham,et al.  Neuropharmacological reassessment of the discriminative stimulus properties ofd-lysergic acid diethylamide (LSD) , 2004, Psychopharmacology.

[8]  David C. Burr,et al.  Using Psilocybin to Investigate the Relationship between Attention, Working Memory, and the Serotonin 1A and 2A Receptors , 2005, Journal of Cognitive Neuroscience.

[9]  J. C. Winter,et al.  Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats , 2005, Psychopharmacology.

[10]  R. Glennon.  Do classical hallucinogens act as 5-HT2 agonists or antagonists? , 1990, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[11]  T. Järbe,et al.  Discriminative response control produced with hashish, tetrahydrocannabinols (δ8-THC and δ9-THC), and other drugs , 2004, Psychopharmacologia.

[12]  E. Slaviero.  HALLUCINOGENIC DRUGS , 1954 .

[13]  R. Schultes,et al.  The Botany and Chemistry of Hallucinogens , 1974 .

[14]  J. C. Winter,et al.  Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs II: reassessment of LSD false positives , 1995, Psychopharmacology.

[15]  J. C. Winter,et al.  The 5-HT1A receptor and the stimulus effects of LSD in the rat , 2005, Psychopharmacology.

[16]  J. B. Appel,et al.  Involvement of 5-HT receptor subtypes in the discriminative stimulus properties of mescaline. , 1989, European journal of pharmacology.

[17]  J. C. Winter,et al.  A 5-HT2C receptor-mediated interaction between 2,5-dimethoxy-4-methylamphetamine and citalopram in the rat , 2004, Pharmacology Biochemistry and Behavior.

[18]  T. Järbe.  LSD-25 as a discriminative stimulus for response selection by pigeons , 1980, Pharmacology Biochemistry and Behavior.

[19]  A. Horita,et al.  Dephosphorylation of Psilocybin to Psilocin by Alkaline Phosphatase , 1961, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[20]  J. C. Winter,et al.  Mescaline and lysergic acid diethylamide (LSD) as discriminative stimuli , 2004, Psychopharmacologia.

[21]  Dori M. Pynnonen,et al.  Serotonergic–dopaminergic mediation of MDMA's discriminative stimulus effects in a three-choice discrimination , 2003, Pharmacology Biochemistry and Behavior.

[22]  S. Peroutka,et al.  Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes , 1990, Neuropharmacology.

[23]  M. D. Schechter.  Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) , 1988, Pharmacology Biochemistry and Behavior.

[24]  J. B. Appel,et al.  Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline. , 1988, The Journal of pharmacology and experimental therapeutics.

[25]  Sidney M. Cohen,et al.  Psychotomimetic agents. , 1967, Annual review of pharmacology.

[26]  T. Branchek,et al.  Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. , 1993, The Journal of biological chemistry.

[27]  J. C. Winter,et al.  Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli , 2004, Psychopharmacology.

[28]  A. Burger.  Drugs Affecting the Central Nervous System , 1968 .

[29]  Alexander T. Shulgin,et al.  Tihkal : The Continuation , 1997 .

[30]  R. Thisted,et al.  Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis , 2005, Psychopharmacology.

[31]  R. Griffiths,et al.  Asymmetrical cross‐generalization in drug discrimination with lorazepam and pentobarbital training conditions , 1989 .

[32]  R. Balster,et al.  An Analysis of the Function of Drugs in the Stimulus Control of Operant Behavior , 1971 .

[33]  H. Isbell.  Comparison of the reactions induced by psilocybin and LSD-25 in man , 2004, Psychopharmacologia.

[34]  Bryan L. Roth,et al.  WAY-100635 is a potent dopamine D4 receptor agonist , 2006, Psychopharmacology.

[35]  D. Spencer,et al.  The interoceptive discriminative stimuli induced by the novel putative anxiolytic TVX Q 7821: behavioral evidence for the specific involvement of serotonin 5-HT1A receptors , 2004, Psychopharmacology.

[36]  R. Mailman,et al.  LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors , 1995, Psychopharmacology.

[37]  J. C. Winter,et al.  The Paradox of 5-Methoxy-N,N-Dimethyltryptamine An Indoleamine Hallucinogen That Induces Stimulus Control Via 5-HT1A Receptors , 2000, Pharmacology Biochemistry and Behavior.

[38]  J. C. Winter.  Stimulus properties of phenethylamine hallucinogens and lysergic acid diethylamide: the role of 5-hydroxytryptamine. , 1978, The Journal of pharmacology and experimental therapeutics.

[39]  D. Jackson,et al.  Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors. , 1993, European journal of pharmacology.

[40]  R. Glennon,et al.  Further studies on N-methyl-1(3, 4-methylenedioxyphenyl)-2-aminopropane as a discriminative stimulus: Antagonism by 5-hydroxytryptamine3 antagonists , 1992, Pharmacology Biochemistry and Behavior.

[41]  Andreas Bäbler,et al.  Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action , 1998, Neuroreport.

[42]  T. Thompson,et al.  Stimulus Properties of Drugs , 1971, Springer New York.

[43]  D. E. Nichols,et al.  Effect of Ring Fluorination on the Pharmacology of Hallucinogenic Tryptamines. , 2001 .

[44]  A. Hofmann,et al.  Identifizierung von Psilocin , 1959, Experientia.

[45]  D. B. Repke,et al.  Anadenanthera: Visionary Plant of Ancient South America , 2006 .

[46]  J. Tinklenberg,et al.  Marihuana and Temporal Disintegration , 1970, Science.

[47]  D. Spencer,et al.  Serotonin receptor subtype mediation of the interoceptive discriminative stimuli induced by 5-methoxy-N,N-dimethyltryptamine , 2004, Psychopharmacology.

[48]  H. Kobel,et al.  Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen RauschpilzPsilocybe mexicana Heim , 1958, Experientia.

[49]  F. Colpaert,et al.  Stimulus properties of drugs : ten years of progress , 1978 .

[50]  R. Glennon,et al.  Pizotyline effectively attenuates the stimulus effects of N-Methyl-3,4-methylenedioxyamphetamine (MDMA) , 2005, Pharmacology Biochemistry and Behavior.

[51]  E. Gouzoulis-Mayfrank,et al.  Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers Results of an experimental double-blind placebo-controlled study , 1999, Psychopharmacology.

[52]  J. C. Winter,et al.  The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs I: Antagonist correlation analysis , 1995, Psychopharmacology.

[53]  J. C. Winter.  Xylamidine tosylate: differential antagonism of the hypothermic effects of N,N-dimethyltryptamine, bufotenine, and 5-methoxytryptamine. , 1972, Archives internationales de pharmacodynamie et de therapie.

[54]  D. D. Godse,et al.  Structure-activity relationships among 5-methoxy-n:n-dimethyltryptamine, 4-hydroxy-n:n-dimethyltryptamine (psilocin) and other substituted tryptamines. , 1968, Life sciences.

[55]  J. C. Winter,et al.  Interactions between serotonergic agonists and antagonists in rats trained with LSD as a discriminative stimulus , 1988, Pharmacology Biochemistry and Behavior.

[56]  R. Mowbray,et al.  HALLUCINOGENS , 1970, The Medical journal of Australia.

[57]  S. Malitz,et al.  Some observations on psilocybin, a new hallucinogen, in volunteer subjects. , 1960, Comprehensive psychiatry.

[58]  J. Rosecrans,et al.  Lysergic acid diethylamide (LSD) as a discriminative cue: Drugs with similar stimulus properties , 2004, Psychopharmacologia.

[59]  L. Hollister.  Clinical, biochemical and psychologic effects of psilocybin. , 1961, Archives internationales de pharmacodynamie et de therapie.

[60]  J. C. Winter,et al.  Behavioral and Biochemical Evidence for a Nonessential 5-HT2A Component of the Ibogaine-Induced Discriminative Stimulus , 1998, Pharmacology Biochemistry and Behavior.

[61]  J. Finlayson,et al.  Protein turnover in glycine-C14-labelled Landschütz ascites tumor cells , 1959, Experientia.

[62]  C. R. Atwell,et al.  Experimental psychiatry. V. Psilocybine, a new psychotogenic drug. , 1960, The New England journal of medicine.

[63]  J. C. Winter.  Hallucinogens as discriminative stimuli. , 1974, Federation proceedings.